The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for widely used treatments from Jazz Pharma.

Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of time someone spends in deep sleep.